The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
In the latest session, Kymera Therapeutics Inc (NASDAQ: KYMR) closed at $85.68 down -4.46% from its previous closing price of $89.68. In other words, the price has decreased by -$4.46 from its previous closing price. On the day, 1.13 million shares were traded. KYMR stock price reached its highest trading level at $90.33 during the session, while it also had its lowest trading level at $84.578.
Ratios:
For a deeper understanding of Kymera Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.38 and its Current Ratio is at 7.38. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.07.
On October 24, 2025, B. Riley Securities reiterated its Buy rating and also lowered its target price recommendation from $60 to $80.
On October 21, 2025, Mizuho started tracking the stock assigning a Outperform rating and target price of $81.Mizuho initiated its Outperform rating on October 21, 2025, with a $81 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 10 ’25 when Booth Bruce sold 229,809 shares for $91.73 per share. The transaction valued at 21,080,724 led to the insider holds 686,477 shares of the business.
Booth Bruce sold 6,101 shares of KYMR for $556,594 on Dec 11 ’25. The Director now owns 685,501 shares after completing the transaction at $91.23 per share. On Dec 12 ’25, another insider, Booth Bruce, who serves as the Director of the company, sold 678 shares for $91.04 each. As a result, the insider received 61,725 and left with 685,393 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KYMR now has a Market Capitalization of 6854316544 and an Enterprise Value of 5742907392. For the stock, the TTM Price-to-Sale (P/S) ratio is 154.68 while its Price-to-Book (P/B) ratio in mrq is 6.50. Its current Enterprise Value per Revenue stands at 131.311 whereas that against EBITDA is -17.861.
Stock Price History:
The Beta on a monthly basis for KYMR is 2.19, which has changed by 1.1200945 over the last 52 weeks, in comparison to a change of 0.12838376 over the same period for the S&P500. Over the past 52 weeks, KYMR has reached a high of $103.00, while it has fallen to a 52-week low of $19.44. The 50-Day Moving Average of the stock is 31.62%, while the 200-Day Moving Average is calculated to be 87.83%.
Shares Statistics:
For the past three months, KYMR has traded an average of 980.07K shares per day and 2056430 over the past ten days. A total of 71.74M shares are outstanding, with a floating share count of 65.45M. Insiders hold about 17.09% of the company’s shares, while institutions hold 91.62% stake in the company. Shares short for KYMR as of 1764288000 were 8686394 with a Short Ratio of 8.86, compared to 1761868800 on 8045538. Therefore, it implies a Short% of Shares Outstanding of 8686394 and a Short% of Float of 14.879999999999999.
Earnings Estimates
Currently, 20.0 analysts are dedicated to thoroughly evaluating and rating the performance of Kymera Therapeutics Inc (KYMR) in the stock market.The consensus estimate for the next quarter is -$0.97, with high estimates of -$0.76 and low estimates of -$1.37.
Analysts are recommending an EPS of between -$2.77 and -$3.86 for the fiscal current year, implying an average EPS of -$3.47. EPS for the following year is -$3.77, with 21.0 analysts recommending between -$2.99 and -$6.01.
Revenue Estimates
A total of 21 analysts believe the company’s revenue will be $14.63M this quarter.It ranges from a high estimate of $52.24M to a low estimate of $3M. As of. The current estimate, Kymera Therapeutics Inc’s year-ago sales were $7.39MFor the next quarter, 21 analysts are estimating revenue of $10.62M. There is a high estimate of $20M for the next quarter, whereas the lowest estimate is $5M.
A total of 22 analysts have provided revenue estimates for KYMR’s current fiscal year. The highest revenue estimate was $105M, while the lowest revenue estimate was $39.1M, resulting in an average revenue estimate of $53.36M. In the same quarter a year ago, actual revenue was $47.07MBased on 22 analysts’ estimates, the company’s revenue will be $47.38M in the next fiscal year. The high estimate is $100M and the low estimate is $10M.
